What blends are
A blend is a single vial containing several peptides at fixed ratios, sold under a brand name. Common examples combine BPC-157, TB-500, GHK-Cu and KPV in various configurations, marketed for recovery, healing or skin.
The names are invented by sellers. They are not compound names, not formulation standards, and not consistent between suppliers. Two vials labelled with the same blend name from different sources may contain entirely different things at entirely different ratios.
The structural problem
Most compounds on this site have thin evidence. Blends have a different problem, and it is worse.
Combining compounds that individually lack efficacy evidence does not produce evidence for the combination. It produces more unknowns in a single vial.
Consider what a blend actually asks you to accept:
- That each component works — mostly unestablished in humans for the compounds typically used.
- That the chosen ratio is correct — never studied. Nobody has run a dose-ratio study on any commercial blend.
- That the components do not interfere with each other — untested. Peptides can compete for transport, degrade one another, or destabilise in solution.
- That the combined safety profile is acceptable — unknowable, since the individual profiles are largely unknown.
Why real combination drugs are different
Legitimate combination products are developed as combinations. The dose relationship between components is studied deliberately, usually across multiple ratios. Interaction is characterised. The combination is then tested against each component alone, to demonstrate the combination is actually better than its parts.
None of this has happened for any peptide blend on sale.
The comparison against monotherapy is the step that matters most, and it is the step blends skip entirely. Without it, "synergy" is an assertion.
The attribution problem
If you use a blend and feel better, you cannot know which component did it, or whether any did. If you have an adverse reaction, you cannot know what caused it — which matters enormously if you need to tell a doctor what you have taken.
This is not a theoretical concern. Presenting at A&E having injected an unlabelled multi-component vial of unknown provenance is a materially worse position than presenting having injected a single identified compound.
Quality control gets harder, not easier
Every additional component multiplies the ways a vial can be wrong. Each has its own identity, purity and stability characteristics. Peptides have different optimal storage conditions and different degradation pathways, and combining them in one solution can accelerate breakdown.
A certificate of analysis for a blend — if one exists at all — would need to verify each component separately. In practice, blend COAs are rare, vague, or simply absent.
Why sellers like blends
Worth naming plainly. Blends carry higher margins, create proprietary-sounding brand names that cannot be price-compared against other sellers, and make it impossible for a buyer to assess whether the quantity of any individual component is adequate. A branded blend is a product; a single compound is a commodity.
Where this leaves you
If you are interested in a compound, the individual compound pages on this site set out what is and is not known about it. A blend does not improve on that position. It adds unverified components, unstudied ratios, and the loss of any ability to attribute effects, in exchange for a name somebody invented.